Escherichia coli cra null mutants have been reported in the literature to be impaired in biofilm formation. To develop E. coli biofilm-inhibiting agents for prevention and control of adherent behaviour, analogues of a natural Cra ligand, fructose-1,6-bisphosphate, were identified based on two-dimensional similarity to the natural ligand. Of the analogues identified, those belonging to the bisphosphonate class of drug molecules were selected for study, as these are approved for clinical use in humans and their safety has been established. Computational and in vitro studies with purified Cra protein showed that risedronate sodium interacted with residues in the fructose-1,6-bisphosphate-binding site. Using a quantitative biofilm assay, risedronate sodium, at a concentration of 300-400 mM, was found to decrease E. coli and Salmonella pullorum biofilm formation by .60 %. Risedronate drastically reduced the adherence of E. coli cells to a rubber Foley urinary catheter, demonstrating its utility in preventing the formation of biofilm communities on medical implant surfaces. The use of risedronate, either alone or in combination with other agents, to prevent the formation of biofilms on surfaces is a novel finding that can easily be translated into practical applications.
INTRODUCTION
Sessile microbial communities growing as biofilms are potential hazards for human health, and are also a major concern in environmental and industrial settings. A number of persistent and chronic bacterial infections, such as periodontitis, otitis media and endocarditis, may be linked to the formation of biofilms. Medical implants such as sutures, dental implants and catheters can be colonized by pathogenic bacteria, which can form biofilms and cause recurrent infections (Donlan & Costerton, 2002) . Sessile bacteria can tolerate host immune responses and are highly resistant to antibiotics and hydrodynamic shear forces (Schembri et al., 2003) . These characteristics are lost once the biofilm is dispersed and the cells revert to a planktonic lifestyle (Costerton et al., 1995) .
Biofilm antibiotic tolerance is of major clinical importance because more than 60 % of bacterial infections in developed countries are considered to be linked to biofilm formation (Costerton et al., 1999) . The annual economic impact of antibiotic-resistant infections has been estimated to be up to US$24 billion in the USA alone (Hall, 2004) .
Antibiotic resistance of biofilm bacteria is a function of cell wall composition, surface structure and changes in the microbial physiology of the biofilm (Evans et al., 1990; Wilson, 1996; Davies et al., 1998; Davies, 2003; Fux et al., 2005) . The negatively charged exopolysaccharide may protect bacteria from cationic antibiotics by restricting their permeation (Stewart, 1996; Anderl et al., 2000) . Biofilms may also interfere with the immune clearance of pathogens (Johnson et al., 1986) .
A number of strategies have been used to prevent biofilm formation and to eradicate existing biofilms. These include preventing the adherence of bacteria to surfaces or other bacteria, interrupting quorum-sensing mechanisms required for the formation of biofilm components, inhibiting biosynthesis of the extracellular components of the biofilm matrix, and employing enzymes that can degrade the biofilm matrix, rendering the bacteria accessible to biocides and/or immune clearance (Cegelski et al., 2008) . In the field of healthcare, some of these approaches have been implemented by using topical antimicrobial ointments, using catheters provided with a surgically implanted cuff (Flowers et al., 1989) , seeding catheters with avirulent urinary tract Escherichia coli isolates (Trautner et al., 2003; Trautner et al., 2007) , and coating medical devices with antimicrobial agents (Darouiche et al., 1999; Johnson et al., 1999; Ahearn et al., 2000; Domenico et al., 2001; Edmiston et al., 2006; Gó mez-Alonso et al., 2007; Cobrado et al., 2012 Cobrado et al., , 2013 Azevedo et al., 2014) .
We have demonstrated that deletion of the gene coding for the catabolite repressor/activator (Cra) protein, which functions as a transcription factor, significantly decreased biofilm formation in E. coli (Reshamwala & Noronha, 2011) . As Cra is conserved in the Enterobacteriaceae, we expect that a similar mutation would result in a similar result in other bacterial species of this family, e.g. Salmonella, Shigella and Yersinia. A cra null mutant represents a case where Cra is not bound to its operator sites on DNA. Physiologically, this is achieved by the binding of ligands such as fructose-1-phosphate and fructose-1,6-bisphosphate to Cra, which dissociates Cra from its binding sites (Ramseier et al., 1995) . The present study was conducted to assess whether analogues of these natural ligands may act as inhibitors of Cra, and may be potential antibiofilm agents.
METHODS
Identification of accessible sites on Cra. An X-ray diffractionderived structure of a truncated Cra molecule (Chang et al., 2006) is available in the RCSB Protein Database (ID 2IKS) (Berman et al., 2000) .
LIGSITE
CSC (Huang & Schroeder, 2006) , a pocket prediction algorithm, was used to predict accessible sites on chain A of the deposited structure (the receptor). The receptor was prepared for docking using the Dock Prep module of CHIMERA (Pettersen et al., 2004) and used for pocket prediction. A probe radius of 5.0 Å was used, and the x, y and z coordinates of the top three active sites were obtained.
Docking of bisphosphonates to Cra. The co-ordinates obtained using LIGSITE CSC (see above) were used for docking bisphosphonates (ligands) to the receptor using the docking programme AutoDock 4.3 (Morris et al., 2009) . GA-LS (Genetic Algorithm -Local Search, also known as a Lamarckian genetic algorithm or LGA), which is a hybrid genetic algorithm with a local search, was used. The ligand and receptor files were prepared in PDBQT format (Gasteiger charges) as required by AutoDock for docking. Selenomethionine in 2IKS was replaced by methionine using CHIMERA.
The grid parameter file (.gpf) was generated using the AutoDock application as follows: the centre of the grid was assigned using x, y and z co-ordinates obtained from LIGSITE CSC (see above); the number of points ranged from 60 to 120 in three directions, and spacing ranged from 0.375 to 1.0 Å . An LGA search was performed to find the 'best scoring' ligand conformation with the number of energy evaluations ranging from 50 000 to 250 000. The output file (.dpf) was sent to LGA. Rigid docking of the ligand into the receptor was performed using AutoDock4. Docking was also carried out using the Glide module (version 6.7), a ligand docking program for predicting protein-ligand binding modes Halgren et al., 2004) , in the Schrödinger Suite 2015-2 (Schrödinger LLC). The Maestro User Interface (version 10.2) was used for preparation of the ligands using the Ligprep module (version 3.4). The Cra protein was prepared using the Protein Preparation Wizard. Selenomethionines were replaced by methionines. The missing side chains were filled using the Prime module (version 4.0). The protein was subjected to restrained minimization with deviations of the heavy atoms from the crystal structure set to a rootmean-square deviation of 0.1. Binding sites on the Cra protein were detected using the SiteMap module (version 3.5). The docking solutions were scored by the Standard Precision (SP-Score) method.
Bacterial strains and growth conditions. E. coli MG1655 (CGSC #6300) was obtained from the Coli Genetic Stock Center, Yale University, USA. Salmonella pullorum is an avian pathogen maintained in the laboratory, originally isolated from a diseased fowl. Bacteria were routinely cultured at 37 uC in Luria-Bertani (LB) medium. Growth was monitored by measuring absorbance at 600 nm. Biofilm assays were carried out at 26 uC in colony-forming antigen (CFA) medium (Evans et al., 1977) containing (l
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) 10 g Casamino acids, 1 g yeast extract, 50 mg MgSO 4 and 5 mg MnCl 2 (pH 7.4) (for E. coli), or in LB medium without NaCl (for S. pullorum). Risedronate sodium, alendronate sodium and ibandronate sodium were kindly provided by Cipla Ltd.
Cloning of the cra gene and purification of 6 3 His-tagged Cra protein. The cra gene was amplified and cloned as described previously (Reshamwala & Noronha, 2011) . The 6|His-tagged Cra protein was purified as described previously (Reshamwala & Noronha, 2011) . The purified protein was stored in 40 % glycerol at 220 uC.
Determination of Cra2ligand interaction using mass spectrometry. Trypsin-mediated proteolysis of Cra and Cra-ligand was carried out in a 300 : 1 protein : enzyme (wt/wt) ratio, according to the method of Shields et al. (2003) . Cra (4 mM) and Cra : ligand mixtures (4 : 40 mM) in 10 mM ammonium acetate (pH 7.7) were incubated at room temperature for 15 min before being digested simultaneously. After incubation at room temperature for 90 min, a 1 ml aliquot of each digest was added to 6 ml 0.1 % trifluoroacetic acid (TFA) to quench trypsin activity.
One microlitre of a-cyano-4-hydroxycinnamic acid (5 mg ml 21 in 0.1 % TFA in 2 : 3 acetonitrile : water) was mixed with 1 ml quenched digest and deposited on a flat stainless steel matrix-assisted laser desorption/ionization (MALDI) sample plate. MALDI mass spectra were acquired on an Axima-CFR (Kratos Analytical; Shimadzu) MALDI time-of-flight (TOF) mass spectrometer equipped with a nitrogen laser (337 nm). Mass spectra were obtained in positive ion and linear modes.
Quantitative biofilm assay. Biofilm formation was quantified using the method of Jackson et al. (2002) . Overnight cultures were inoculated 1 : 100 into fresh medium in new borosilicate glass tubes (75|12 mm). Growth of planktonic cells was determined by absorbance at 600 nm. Biofilm was measured by discarding the medium, rinsing the tubes three times with water and staining bound cells with 1 % crystal violet for 15 min. The dye was solubilized with 33 % acetic acid, and absorbance at 630 nm was determined. For each experiment, background staining was corrected by subtracting the crystal violet bound to uninoculated controls.
Inhibition of biofilm formation on a Foley urinary catheter.
E. coli MG1655 was inoculated in CFA medium in which 1-inch sections of Foley rubber urinary balloon catheter (Rusch; Teleflex Medical Private Ltd) were placed, and incubated at 26 uC for 48 h. The catheter sections were then rinsed three times with phosphate buffer to remove non-adherent cells, stained with acridine orange (30 mg ml
S. M. S. Reshamwala and others

21
) and observed using a 60u water immersion objective in a FV 500 laser-scanning confocal microscope (Olympus) housed in the Sophisticated Analytical Instruments Facility (SAIF) at the Indian Institute of Technology Bombay, Mumbai, India.
Quantification of bacteria bound to gauze swabs. Risedronate sodium was impregnated in commercially available sterile absorbent gauze swabs (Softouch) by placing the swabs in 500 and 1000 mM risedronate sodium aqueous solutions for 18 h. The swabs were incubated with 5|10 5 c.f.u. E. coli ml 21 in CFA medium at 26 uC for 1 h to allow cells to bind to the swab material. The swabs were rinsed three times with saline to remove unbound and loosely bound cells. Cells bound to the swab material were dislodged by placing the swabs in a bath sonicator for 10 min. The sonicate was diluted and plated on MacConkey agar plates to quantify bound cells.
RESULTS AND DISCUSSION
Identification of molecules similar to fructose-1,6-phosphate Fructose-1-phosphate (the product of phosphotransferase system-catalysed fructose group translocation) and fructose-1,6-bisphosphate are the natural ligands of Cra. Micromolar concentrations of fructose-1-phosphate or millimolar concentrations of fructose-1,6-bisphosphate displace this transcription factor from DNA (Ramseier et al., 1995) . We hypothesized that molecules structurally similar to these natural effectors might function to displace Cra from its binding sites on DNA. As Cra is required for biofilm formation in E. coli, such analogues may have potential antibiofilm properties.
The SuperDrug Database (Goede et al., 2005) was queried to identify drug molecules bearing a two-dimensional (2D) similarity to fructose-1,6-bisphosphate. Six of the identified molecules were members of the bisphosphonate class of drugs; the rest were organic and inorganic salts, and radioactive nuclides ( Table 1) . As the latter two classes of molecules may be highly non-specific and cytotoxic, respectively, bisphosphonates were chosen for further study.
Bisphosphonates are synthetic compounds characterized by a P-C-P group. They are used in medicine to prevent loss of bone mass by inhibiting bone resorption, and are approved for systemic use in humans to prevent and treat a number of diseases, including osteoporosis, osteitis deformans, bone metastasis, multiple myeloma, primary hyperparathyroidism, osteogenesis imperfecta and other conditions that involve bone fragility. The biological effects of bisphosphonates consist mainly of inhibition of bone resorption and, when administered in large amounts, inhibition of ectopic and normal calcification (Fleisch, 2002) .
Non-nitrogen-containing bisphosphonates act by inhibiting osteoclast function via metabolism into toxic ATP metabolites, which leads to apoptosis of osteoclasts (Frith et al., 1997; van Beek et al., 2003) . Nitrogen-containing bisphosphonates such as risedronate and ibandronate exert their antiresorptive action by inhibiting farnesyl diphosphate synthase and suppressing protein geranylgeranylation, which are required for osteoclastic bone resorption (van Beek et al., 1999; Reszka & Rodan, 2003) .
In silico docking of bisphosphonates to Cra
In general, structure-based drug design involves prediction of protein-ligand complexes. Predicting the binding site on the surface of a protein (receptor) is a prerequisite step in structure-based drug design. The complete structure of Cra has not been reported, although a nuclear magnetic resonance-derived structure of the N terminus (Penin et al., 1997) and an X-ray diffraction-derived structure of a truncated Cra molecule (Chang et al., 2006) are reported and available in the RCSB Protein Database (Berman et al., 2000) . Using the latter structure, LIGSITE CSC (Huang & 
Risedronate binds to Cra in vitro
Although nuclear magnetic resonance and X-ray crystallography are commonly employed to determine proteinligand binding sites and protein conformation changes induced by complex formation, limited proteolysis coupled to mass spectrometry has also been demonstrated to provide important information about solution-phase protein structural changes by determining intermediates in protein folding studies (Leite et al., 2000) and mapping interfaces in protein-protein (Spolaore et al., 2001 ) and protein-DNA (Cohen et al., 1995) complexes.
Trypsin-mediated proteolysis was used to determine protein-ligand non-covalent binding sites and protein conformational changes due to ligand binding. Trypsin cleaves peptide chains at the carboxyl-terminal side of the amino acids lysine or arginine, except when either is followed by proline (Olsen et al., 2004) . Changes in surface topology due to ligand binding can be inferred by comparing the relative ion abundances of peptides released from proteolysis of protein and protein-ligand complexes. A decrease in ion abundance suggests that the ligand obstructs the access of the protease to specific sites on the protein, identifying ligand-binding site(s) (Shields et al., 2003) .
Fructose-1,6-bisphosphate, risedronate, alendronate and ibandronate were mixed with Cra and incubated to allow complex formation. Trypsin was used to digest accessible sites on the protein, and ion abundances of the peptides released were compared using mass spectrometry. Peaks obtained from mass spectrometry were assigned to individual peptides based on the predicted mass of peptides released after trypsin-mediated cleavage of Cra (Wilkins et al., 1997; Gasteiger et al., 2005) (Table 2 ).
In the proteolysis of the Cra-fructose-1,6-bisphosphate and Cra-risedronate complexes relative to that of Cra (Fig. 1) , there was a reduction in the relative ion abundance of tryptic peptides at m/z 636 (E198-R202) and m/z 674 (V38-R43). This suggested that these ligands reduced the ability of the protease to access specific amino acids, such as R43 and R202, either by physically blocking these sites or by altering the tertiary structure so as to reduce the rate of proteolysis at these sites.
An increase in relative ion abundance of tryptic peptides at m/z 1788 (S63-R78) and m/z 1176, which may correspond to a peptide with a missed cleavage site at K37 (T34-R43), was also observed. This suggests that binding of the ligands reduces trypsin's ability to cleave at K37, and induces a conformational change that increases the susceptibility of cleavage at R78. The computationally predicted risedronate binding site (Fig. 2) is consistent with experimental data. The ligand interacts with N73, S75 and Y76, which may expose R78 and make it more accessible to trypsin.
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As shown in Fig. 1 , the peptides released from trypsin digestion of Cra : risedronate and Cra : fructose-1,6-bisphosphate mixtures were similar, indicating that both these molecules bind to the same site on Cra. In contrast, the pattern of peptides released from trypsin digestion of the Cra : alendronate and Cra : ibandronate mixtures differed from that of trypsin digestion of Cra alone. This suggests that alendronate and ibandronate do not bind to Cra in the fructose-1,6-bisphosphate-binding site, which was supported by docking studies using Glide (data not shown).
Risedronate inhibits E. coli biofilm formation
Risedronate sodium was tested for its biofilm inhibition property using E. coli MG1655 and an avian pathogenic S. pullorum strain. Risedronate sodium was found to decrease biofilm formation by w60 % at a concentration of *300-400 mM (Fig. 3) , and was comparable to the decrease in biofilm formation observed in a cra mutant (Reshamwala & Noronha, 2011) . No difference in planktonic growth was observed in the presence of 350 mM of risedronate (data not shown).
Long-term indwelling bladder catheterization is often complicated by catheter blockage (Kohler-Ockmore & Feneley, 1996) . Bacteria colonize the catheter surface and grow as biofilms (Williams & Stickler, 2008) , which necessitates frequent changing of the catheter. Hence, E. coli biofilm formation on a rubber Foley catheter in the presence of risedronate was studied. Risedronate sodium at a concentration of 400 mM was effective in drastically reducing biofilm formation, as assessed by confocal microscopy (Fig. 4) , demonstrating the utility of this molecule in preventing formation of biofilm communities on medical implant surfaces.
As bandaging material is prone to fouling by exudates that may contain and attract bacteria, risedronate was also impregnated in gauze swabs, and the adherence of E. coli cells to the impregnated material was studied. Adherence of E. coli to gauze swabs impregnated with 500 and 1000 mM risedronate was found to be reduced by 75 % (Fig. 5) , indicating that risedronate affected the initial binding of cells, the first step towards biofilm formation. Risedronate could therefore be impregnated in bandages and suture material to prevent bacterial adherence and establishment of infection.
Exploring Cra inhibitors as antibiofilm agents
Risedronate is structurally similar to fructose-1,6-phosphate, the natural effector of Cra (Ramseier et al., 1995) , and binds to Cra in the same region as fructose-1,6-bisphosphate (see above). Thus, risedronate may act as a biofilm inhibitor by interfering with the normal functioning of Cra, which is required for biofilm formation; however, the precise mode of action of the biofilm-inhibiting activity of risedronate is not clear. Residronate may also interfere with other cell processes through specific or non-specific interactions, which cannot be ruled out.
Nitrogen-containing bisphosphonates inhibit farnesyl diphosphate synthase in osteoclasts (van Beek et al., 1999; Reszka & Rodan, 2003) . Therefore, E. coli farnesyl/geranyl diphosphate synthase, the product of the ispA gene, may also be a target for risedronate, although it shares only 30 % similarity with its human counterpart. ispA null mutants are viable, and have no obvious phenotype regarding their growth properties (Fujisaki et al., 2005) . ispA has also been reported to be essential for growth in E. coli BW25113 (Baba et al., 2006) . Growth of the mutants has been reported to be 70-80 % of that of the WT strain Fig. 2 . Docking of risedronic acid to Cra in the predicted binding site using Glide Halgren et al., 2004) . The interacting amino acid side chains are indicated. The ligand is predicted to form a salt bridge with R323, hydrogen bonds with D148, N73, S75, R197 and R323 and has a hydrophobic interaction with Y76. Fig. 3 . Effect of risedronate sodium on biofilm formation by E. coli MG1655 in CFA medium (a) and S. pullorum in LB medium without NaCl (b), both at 26 8C. Each bar shows the mean¡SD of at least two separate experiments, and asterisks indicate statistically significant results (*P,0.005; **P,0.05).
Use of risedronate as an antibiofilm agent under aerobic conditions, and the same as the WT under anaerobic conditions (Fujisaki et al., 2005) . The mutant contains less than 13 and 18 %, respectively, of ubiquinone-8 and menaquinone-8 and 40-70 % of the WT levels of undecaprenyl phosphate, although a low level of geranyl diphosphate synthase activity has been reported in ispA null mutants, which may be due to the activity of other prenyltransferases (Fujisaki et al., 1989 (Fujisaki et al., , 2005 Saito et al., 2007) . The effects of these changes on biofilm formation have not been studied.
To conclude, microbial fouling is a common problem in a variety of industrial, household, personal hygiene and medical settings (Yang & Givskov, 2015) . A critical need exists for improved microbial control methods that are effective, economic, non-toxic and environmentally friendly. Risedronate is approved for systemic use in humans, and is safe and relatively cheap. This study is the first to show antibiofilm activity of risedronate. Further experimentation is required to elucidate the mechanism(s) whereby risedronate exerts its antibiofilm effect. Nevertheless, the use of risedronate, either alone or in combination with other agents, to prevent the formation of biofilms on surfaces is a novel finding that can easily be translated into practical applications. This can be in the form of coatings on materials used to manufacture catheters, sutures and bandaging material, or as a dusting powder on bandages used to cover wounds. As the envisaged use of risedronate is not systemic, side effects observed when this drug is administered orally may not be a concern and higher concentrations may be safely employed. 
